Vertex Pharmaceuticals (VRTX)

The methods disagree: one places the value today above the price ($507) and the other below.

Today — fairly valued: at $507 trades ~2.9% below its value discounted to today (~$522); the discount is positive but does not reach the margin of safety we require (≥38%).

At 5 years — En valor: the target price ($651) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.

The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$324.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($507) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The price discounts growth (12.4%/year) above our base case (8.6%/year) → it is priced for a demanding scenario and leaves little cushion against a slowdown.

That growth implies ~$5.4 bn of owner earnings in year 5 (vs ~$4.6 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). Cash accumulates the retained surplus —what is not returned as dividend or buyback—, so that EV falls and multiples compress going forward. The valuation is done on EV/EBIT (normalizado). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Rolling grid: year 0 is the real TTM (revenue $12.587bn to Jun-2026, XBRL). Vertex is a specialty pharmaceutical company dominant in cystic fibrosis (CF): TRIKAFTA/KAFTRIO + ALYFTREK account for ~93% of product revenue (FY2025); the rest comes from CASGEVY (cell/gene therapy) and JOURNAVX (non-opioid acute pain, launched in 2025), both still small but with real early traction. It is valued on EV/EBIT over normalized operating income — the pharmaceutical archetype, band 14-22× —: GAAP FY2024 was depressed (EBIT −$232.9M) by a $4.4bn acquired in-process research and development charge from the Alpine Immune Sciences purchase (a one-off, already outside the TTM window). The revenue starting point (+10%) is the average of the trajectory FY23 +10.5% / FY24 +11.7% / FY25 +8.9% / TTM +10.1% (a relatively narrow band, with no clear trend of acceleration or deceleration), decaying toward +7% by year 5 as the CF franchise —already at ~75% penetration in developed markets— matures and growth comes to depend more on CASGEVY/JOURNAVX/povetacicept. The operating margin compresses modestly in the near term (qualitative guidance of higher cost of goods sold on non-CF products and higher commercial spending on JOURNAVX/povetacicept) and recovers toward year 5 with scale. The 18× exit multiple —within the band, without the patent cliff discount that penalizes other pharmaceutical companies in the library— compresses from today's entry multiple. Cash accumulates: the business retains ~47% of its real free cash flow today (TTM buybacks $2.006bn, no dividend) on a balance sheet with practically no debt and more than $13bn in cash and liquid investments; net buybacks (~1.2%/year, funded with FCF) reduce the share count in the explicit path. Watch: the conversion of CASGEVY/JOURNAVX/povetacicept into material revenue —the pipeline itself has already shown it can fail (VX-264 discontinued, adverse signals from VX-993)— and regulatory pricing pressure (state affordability boards, the CMS GUARD model).

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (EV falls as cash increases). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $651 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $507, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $651 in 5 years and a required return of 4.5% annually, the maximum to pay today is $522. Against the current market price ($507), the margin of safety is 2.9% (trades below the maximum → there is margin) and the total return at that price would be 5.1% annually.

• Multiple vs. quality. 18× EV/EBIT (base) within the pharmaceutical band [14-22×] — without the patent-cliff discount that weighs on other pharmaceuticals in the library.
• Reverse-DCF. The price already discounts growth close to the base case; little margin for the market to be wrong in our favor.
• Margin of safety. Total return ~+5% (all price appreciation, no dividend) — just above the method's 4% floor, a limited margin.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ High incremental ROIC (compounding)
• ! CFROIC backs up the ROIC (75%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• ROIC exceeds the cost of capital. ROIC well above the 10% bar — exceptional, on invested capital that is small relative to NOPAT because the balance sheet is dominated by cash and investments.
• Margin and stability. TTM operating margin ~38%, with the new-modality pipeline pressuring the cost mix (CASGEVY has far more expensive manufacturing).
• Quality of cash. Owner earnings (~US$2,900 million) is lower than accounting NOPAT/EBIT due to the real working-capital investment behind the CASGEVY/JOURNAVX/ALYFTREK ramp — not an accrual, but genuine reinvestment.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

Vertex's engine is patients treated times net realized price, within a CF franchise that has already reached high penetration (nearly three-quarters of eligible patients). Additional growth comes from conversion to ALYFTREK (same patient, better profile) and from the early ramp — still small in the consolidated base — of CASGEVY (cell/gene therapy) and JOURNAVX (non-opioid acute pain, more than 550,000 prescriptions in its first ten months).

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Real, not nominal. Reported growth (+8.9% FY2025) is almost entirely the combined CF franchise; TRIKAFTA alone grows only +0.7% due to patient migration to ALYFTREK.
• Growth engine. Patient conversion within the CF franchise plus the early ramp of CASGEVY/JOURNAVX, still small within the consolidated base.
• Deceleration and cycle. Decelerates from ~10% toward a ~7% terminal rate as CF matures (nearly three-quarters penetration) and growth comes to depend on the new franchises.

• Relevant in 10 years (recurrence). A cystic fibrosis franchise with lifelong chronic therapy; the pipeline diversifies into gene therapy and non-opioid pain. Very high recurrence.
• Pricing power. Defended by patents and regulatory exclusivity. The only affordability review already resolved (Colorado on TRIKAFTA) concluded the product was ineligible for an upper payment limit, though regulatory pressure (CMS's GUARD model) keeps expanding and is not predictable.
• Moat and its direction. Wide and stable moat: dominant CF position, patents with no near-term cliff, plus the manufacturing barrier for CASGEVY.
• Capital cycle. Sector with high barriers to entry (R&D plus regulation); the risk is not direct competition but the expansion pipeline itself failing, as already happened with VX-264 and VX-993.

• ✓Leverage (net debt / EBITDA)Net cash $13 bn
• –Interest coverage (EBIT / interest)no data
• –Liquidity (current ratio)no data
• !Cash quality (CFROIC vs ROIC)CFROIC backs 75% of ROIC
• ✓Value creation (ROIC − 10% bar)+53pp
• !Malinvestment test (capex vs incremental ROIC)Strong investment mode 2.2x
• !Float / working capitalConsumes cash $1 bn (positive WC)
• !Dilution (SBC % of revenue + shares)SBC 5.5% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Leverage. Nearly free of long-term debt (the 10-K FY2025 reports no long-term debt lines in the consolidated balance; the only credit facility is an unused US$500 million revolver)—an exceptional balance sheet.
• Coverage and cash. US$12,320.4 million in cash and liquid investments (shareholders' equity US$18,665.8 million, long-term debt ~US$0) as of December 31, 2025. Finances the pipeline without leverage.
• Regulatory pricing risk. The Colorado PDAB subjected TRIKAFTA to an affordability review and concluded it was ineligible for an upper payment limit — a favorable precedent, though CMS's GUARD model (most-favored-nation pricing) is an expanding and unpredictable headwind.

• Skin in the game. No insider ownership data in this pass (DEF 14A proxy not available); a CEO with an internal career (Kewalramani, Chief Medical Officer since 2018, CEO since 2020).
• Capital allocation. Active buyback (~US$2,006 million TTM, ~53% of real free cash flow) with no dividend, funded entirely with own cash; a balance sheet with no long-term debt enables opportunistic acquisitions (Alpine, 2024).
• Integrity / normalization. FY2024, with negative operating income and net income due to the Alpine charge (US$4,400 million), is disclosed transparently in the notes.

• There is no clear source of discount: The price already reflects strong results from the CF franchise and the JOURNAVX launch.
• The market already recognizes the quality of the business (ROIC well above the 10% bar, balance sheet nearly free of long-term debt) and pays a quality multiple within the pharmaceutical band, without the patent cliff discount that penalizes other pharmaceuticals in the library.
• The known risk (CF concentration, a binary pipeline beyond that franchise) is already reflected in the price; there is no evidence of forced selling or a lack of analyst coverage.

The 8-K of May 4, 2026 (first quarter results) reiterated full-year 2026 revenue guidance of US$12,950-13,100 million—including US$500 million or more from non-CF products; the current model projection falls between 0.9% and 1.8% above that annualized guidance, an immaterial difference that did not warrant re-anchoring the projection. Without clear missing buyers or motivated sellers → it is not cheap: it is a business of exceptional quality at a price that already reflects it, with limited margin of safety.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -3%/year (-16% total): the margin of safety protects the downside. The bull (+11%/year, +71% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Concentration in cystic fibrosis. Virtually all product revenue depends on the CF franchise (TRIKAFTA/KAFTRIO/ALYFTREK) — the structural disconfirmer.
• Clinical concentration within the CF franchise. TRIKAFTA/KAFTRIO and ALYFTREK share at least one active ingredient: the December 2024 labeling modification for liver damage in TRIKAFTA—which elevated the warning to the FDA's highest category—was replicated in ALYFTREK. A safety issue in one product propagates to the others.
• Binary pipeline. VX-264 missed its efficacy endpoint (type 1 diabetes, discontinued, US$379.0 million charge). Separately, in August 2025 the FDA signaled it did not see a clear path to a broad peripheral neuropathic pain label for suzetrigine (the pain franchise's most advanced asset), coinciding with phase 2 data for VX-993 in acute pain showing it was not superior to suzetrigine, leading to its discontinuation as monotherapy — expansion beyond CF is not guaranteed.
• ALYFTREK royalty arbitration. Ongoing litigation over royalties ceded by the Cystic Fibrosis Foundation; an adverse outcome raises future cost of goods sold.
• Regulatory pricing pressure. CMS's GUARD most-favored-nation pricing model on TRIKAFTA/ALYFTREK; the only precedent already resolved (Colorado on TRIKAFTA) was favorable, but it is not predictive of future reviews.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  A wide moat and ROIC 63% above the 10% bar, but the margin is limited (+3%) → excellent business at a fair price.

• Peter Lynch Growth at a reasonable price (GARP)

  A fast grower growing 9% at a multiple/growth of 2.8 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 4% (EBIT/EV) + ROIC 63% → falls outside the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts 12% vs our 9%: priced for perfection, no favorable mispricing.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -3%/yr, bull-scenario ceiling +11%/yr over 5y: reasonable asymmetry, without an ample cushion.

• Pat Dorsey Moat strength (Five Rules)

  A wide moat, stable; sources: intangibles, efficient scale, cost advantage, switching costs → passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  The price implies 12% vs our 9%: coherent, but at the optimistic end of the range.